235 related articles for article (PubMed ID: 27082431)
1. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Shen K; Xiong T; Tan SC; Wu J
PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza.
Lavelle TA; Uyeki TM; Prosser LA
J Pediatr; 2012 Jan; 160(1):67-73.e6. PubMed ID: 21917267
[TBL] [Abstract][Full Text] [Related]
3. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada.
O'Brien BJ; Goeree R; Blackhouse G; Smieja M; Loeb M
Value Health; 2003; 6(2):116-25. PubMed ID: 12641862
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
Talbird SE; Brogan AJ; Winiarski AP; Sander B
Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
[TBL] [Abstract][Full Text] [Related]
5. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Bellantonio S; Rose DN
Ann Intern Med; 2003 Sep; 139(5 Pt 1):321-9. PubMed ID: 12965940
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Talbird SE; Brogan AJ; Winiarski AP
Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.
Postma MJ; Novak A; Scheijbeler HW; Gyldmark M; van Genugten ML; Wilschut JC
Pharmacoeconomics; 2007; 25(6):497-509. PubMed ID: 17523754
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan.
Nagase H; Moriwaki K; Kamae M; Yanagisawa S; Kamae I
Value Health; 2009; 12 Suppl 3():S62-5. PubMed ID: 20586984
[TBL] [Abstract][Full Text] [Related]
9. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
[TBL] [Abstract][Full Text] [Related]
10. Antiviral agents for influenza: a comparison of cost-effectiveness data.
Lynd LD; Goeree R; O'Brien BJ
Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
[TBL] [Abstract][Full Text] [Related]
11. Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness.
Bruyndonckx R; Bilcke J; van der Velden AW; Li X; Hens N; Coenen S; Butler CC; Beutels P
Value Health; 2022 Feb; 25(2):178-184. PubMed ID: 35094790
[TBL] [Abstract][Full Text] [Related]
12. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Fisher D; Kelly B; Rose DN
Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.
Wu DBC; Chaiyakunapruk N; Pratoomsoot C; Lee KKC; Chong HY; Nelson RE; Smith PF; Kirkpatrick CM; Kamal MA; Nieforth K; Dall G; Toovey S; Kong DCM; Kamauu A; Rayner CR
Epidemiol Infect; 2018 Mar; 146(4):496-507. PubMed ID: 29446343
[TBL] [Abstract][Full Text] [Related]
14. Management of influenza symptoms in healthy adults.
Rothberg MB; He S; Rose DN
J Gen Intern Med; 2003 Oct; 18(10):808-15. PubMed ID: 14521643
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of "test" versus "treat" patients hospitalized with suspected influenza in Hong Kong.
You JH; Chan ES; Leung MY; Ip M; Lee NL
PLoS One; 2012; 7(3):e33123. PubMed ID: 22479363
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
Postma MJ; Beardsworth P; Wilschut JC
J Med Econ; 2008; 11(4):743-68. PubMed ID: 19450079
[TBL] [Abstract][Full Text] [Related]
18. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
Sander B; Hayden FG; Gyldmark M; Garrison LP
Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC
Li X; Bilcke J; van der Velden AW; Bruyndonckx R; Coenen S; Bongard E; de Paor M; Chlabicz S; Godycki-Cwirko M; Francis N; Aabenhus R; Bucher HC; Colliers A; De Sutter A; Garcia-Sangenis A; Glinz D; Harbin NJ; Kosiek K; Lindbæk M; Lionis C; Llor C; Mikó-Pauer R; Radzeviciene Jurgute R; Seifert B; Sundvall PD; Touboul Lundgren P; Tsakountakis N; Verheij TJ; Goossens H; Butler CC; Beutels P;
Eur J Health Econ; 2023 Aug; 24(6):909-922. PubMed ID: 36131214
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.
Vindt Holm M; Gyldmark M; Holme Hansen E
Pharm World Sci; 2004 Dec; 26(6):339-45. PubMed ID: 15683104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
